Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna specialty medication dosing limits Coverage …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy N/A

    Medical Specialty Medication Quantity Limits — Maximum Dosing Regimens and Quantity Limits (Actemra and multiple specialty medications)

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical specialty medication quantity limits and maximum dosing regimens for Actemra (tocilizumab) and other specialty medications by diagnosis, route, age and weight for members covered by Aetna.

    Policy Summary
    PayerAetna
    PolicyMedical Specialty Medication Quantity Limits — Maximum Dosing Regimens and Quantity Limits (Actemra and multiple specialty medications)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionWhen requesting coverage, document the diagnosis and member weight/age and ensure prior authorization requests and dosing do not exceed the listed maximum dosing regimens for the specified diagnosis and route.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10/1/2025Effective date shown for Actemra entries
    Effective 10/1/2025Effective date stated for entries
    ≥10 medicationsDistinct products with dosing entries
    ≈20Distinct medication entries in excerpt
    >=2Pediatric weight‑/age‑based dosing entries

    Coverage Criteria — Maximum Dosing Regimens and Quantity Limits

    Maximum Dosing Regimens by Indication

    Allowed maximum intravenous dosing regimens for Actemra by diagnosis (covered when administered at or below the listed regimen):

    Castleman Disease: IV 8 mg/kg every 2 weeksnone

    chunk 0

    Cytokine Release Syndrome (pediatric): IV dosing: ≥2 years and <30 kg: 12 mg/kg (up to a maximum of 800 mg); ≥30 kg: 8 mg/kg (up to a maximum of 800 mg); no more than 4 total doses given at least 8 hours apartage and weight-based

    chunk 0

    Giant Cell Arteritis: IV ≥18 years: 6 mg/kg (up to maximum of 600 mg) every 4 weeks
    Policy Summary
    PayerAetna
    PolicyMedical Specialty Medication Quantity Limits — Maximum Dosing Regimens and Quantity Limits (Actemra and multiple specialty medications)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionWhen requesting coverage, document the diagnosis and member weight/age and ensure prior authorization requests and dosing do not exceed the listed maximum dosing regimens for the specified diagnosis and route.
    SourceLink
    On This Page
    Coverage Criteria — Maximum Dosing Regimens and Quantity LimitsCoding and Quantity Limit DetailsProvider Actions — Prior Authorization, Documentation, and Denial RiskBackgroundDefinitions and Dosing Terms
    adult

    chunk 0

    Immune Checkpoint Inhibitor-Related Toxicities: IV 8 mg/kg every 4 weeksnone

    chunk 0

    Polyarticular or Oligoarticular Juvenile Idiopathic Arthritis: IV ≥2 years: <30 kg: 10 mg/kg every 4 weeks; ≥30 kg: dosing as listed in sourceage and weight-based

    chunk 0

    Polymyalgia Rheumatica: IV 8 mg/kg every 4 weeksnone

    chunk 1

    Rheumatoid Arthritis: IV ≥18 years: 8 mg/kg (up to maximum of 800 mg) every 4 weeksadult

    chunk 1

    Systemic Juvenile Idiopathic Arthritis: IV ≥2 years: <30 kg: 12 mg/kg every 2 weeks; ≥30 kg: dosing as listed in sourceage and weight-based

    chunk 1

    Bevacizumab (Alymsys/Avastin) — intravitreal and IV dosing limits

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis and route.

    Bevacizumab intravitreal (ophthalmic indications): For diagnoses such as neovascular AMD, diabetic macular edema, proliferative diabetic retinopathy, polypoidal choroidal vasculopathy and retinopathy of prematurity: intravitreal dosing per affected eye as listed (examples: 1.25 mg or 1.5 mg every 4 weeks for adults; 2.5 mg every 4 weeks for PCV; 0.625 mg single dose for ROP in neonates). Frequency: no more frequent than every 4 weeks unless a single-dose pediatric indication.per-eye mg and interval as listed

    See chunks 18,35

    Bevacizumab IV — oncology dosing limits

    Covered when IV dosing matches the specified mg/kg and interval for the listed malignancies and systemic conditions.

    Bevacizumab IV (oncology): Indications (examples): renal cell carcinoma, colorectal cancer, NSCLC, ovarian and gynecologic cancers, hepatocellular carcinoma, various sarcomas and mesotheliomas — IV dosing per indication as listed (examples include 5 mg/kg every 2 weeks; 7.5 mg/kg every 3 weeks; 10 mg/kg every 2 weeks; 15 mg/kg every 3 weeks).mg/kg and interval as listed

    See chunks 18,33,36

    Asceniv (IVIG) — dosing limits by indication

    Covered when Asceniv dosing follows the per-diagnosis weight-based or fixed dosing regimens as listed.

    Asceniv (IVIG) — indication-specific dosing: Conditions include CIDP, Guillain-Barré syndrome, Kawasaki syndrome, ITP, primary immunodeficiency, transplant-related uses, HLH/MAS, and others: dosing ranges from single 400 mg/kg doses for post-exposure prophylaxis to 2 g/kg divided over 2–5 days for acute indications; maintenance regimens include 1 g/kg every 3 weeks, 800 mg/kg every 3 weeks, and product- and indication-specific schedules (e.g., solid-organ transplant allosensitized 3 g/kg divided over 2–5 days).per-indication mg/kg and schedule as listed

    See chunks 20,24,30

    Avsola (Infliximab-axxq) — dosing limits

    Covered when Avsola dosing follows the listed induction and maintenance schedules for the specified diagnoses and age groups.

    Avsola (Infliximab-axxq): Examples: acute graft-versus-host disease: 10 mg/kg every week; ankylosing spondylitis/axial SpA: initial 5 mg/kg at weeks 0, 2, 6 then maintenance 5 mg/kg every 6 weeks; Crohn's disease: induction 5 mg/kg at weeks 0, 2, 6 with maintenance every 8 weeks (pediatric/adult dosing shown), with maximum induction/maintenance dosing up to 10 mg/kg in specified circumstances.weight-based induction/maintenance dosing as listed

    See chunk 37

    Bevacizumab dosing limits

    Coverage is limited to the diagnosis-specific maximum dosing regimens shown; items are covered when dosing and route match the listed regimen for the indicated diagnosis.

    Bevacizumab (Avastin/Avzivi) oncology indications: Covered when dose and frequency do not exceed the diagnosis-specific IV regimens (examples: 5 mg/kg every 2 weeks; 7.5 mg/kg every 3 weeks; 10 mg/kg every 2 weeks; 15 mg/kg every 3 weeks) as listed for the specific malignancy.see per-diagnosis mg/kg and frequency limits

    Includes intravitreal limits for ocular indications (see intravitreal entries).

    Avsola dosing limits

    Covered when dosing follows the listed induction and maintenance schedules and maximum maintenance/induction doses.

    Avsola indications: Coverage allowed for multiple indications with age-stratified dosing and specified induction/maintenance: examples include ankylosing spondylitis (≥18 yrs) initial 5 mg/kg weeks 0,2,6 then maintenance 5 mg/kg every 6 weeks; Crohn's and ulcerative colitis induction 5 mg/kg weeks 0,2,6 with maintenance every 8 weeks and permitted maximum induction/maintenance up to 10 mg/kg for certain situations; many inflammatory and dermatologic indications list 10 mg/kg every 4 weeks or tailored schedules.per-indication mg/kg and frequency as listed

    Some indications permit increased dosing/frequency for incomplete response (see source).

    Avtozma dosing limits

    Covered when dosing matches the listed IV regimens by indication and pediatric weight bands.

    Avtozma indications: Coverage allowed for Castleman disease, CRS, GCA, juvenile idiopathic arthritis forms, RA: examples include 8 mg/kg every 2 weeks for Castleman disease; CRS dosing by weight with max 800 mg and limit of no more than 4 total doses at least 8 hours apart; RA dosing 8 mg/kg every 4 weeks (up to 800 mg); pediatric weight cutoffs apply as specified.per-indication mg/kg, age and weight cutoffs

    See chunks 40-42 for specifics.

    Bavencio dosing limits

    Covered when administered IV at or below the listed dosing frequency.

    Bavencio indications: Maximum dosing regimen listed as 800 mg IV every 2 weeks for multiple indications (e.g., endometrial carcinoma, Merkel cell carcinoma, RCC, thymic carcinoma, urothelial carcinoma, gestational trophoblastic neoplasia).800 mg every 2 weeks

    See chunks 47,48

    Benlysta dosing limits

    Covered when administered per the listed IV regimen for lupus indications.

    Benlysta IV for SLE/LN: Initial: 10 mg/kg IV every 2 weeks for 3 doses; Maintenance: 10 mg/kg IV every 4 weeks for patients ≥5 years.10 mg/kg induction and maintenance

    See chunks 48-49

    IVIG (Bivigam) dosing limits

    Covered when dosing adheres to the indication-specific IVIG regimens provided.

    Bivigam / IVIG indications: Multiple IVIG dosing regimens by diagnosis: common regimens include 2 g/kg per treatment divided over 2–5 days for many autoimmune and neurologic conditions; 400 mg/kg every 3 weeks for CLL; 800 mg/kg every week for BMT/HSCT support; 500 mg/kg every 4 weeks for hypogammaglobulinemia after CAR‑T; 400 mg/kg once within 6 days for measles prophylaxis; pediatric Kawasaki dosing 2 g/kg single dose. Maintenance schedules per indication are listed (e.g., CIDP maintenance 1 g/kg every 3 weeks).per-diagnosis mg/kg and frequency limits

    See chunks 49-55

    Maximum dosing/frequency coverage rules

    Coverage is limited to the maximum dosing regimens and frequencies specified for each listed diagnosis and age/weight group.

    Bivigam dosing per indication: Examples include 2 g/kg divided over 2–5 days (repeat intervals per indication), 800 mg/kg every 3 weeks for some transplant/malignancy indications, 400 mg/kg once for measles/varicella prophylaxis within specified windows, and maintenance regimens such as 1 g/kg every 2–6 weeks for certain chronic conditions.see per-indication dosing

    See chunks 55-63

    BKEMV (eculizumab-aaeb): aHUS/gMG/PNH dosing with initial/maintenance and pediatric weight bands as specified (e.g., initial 900 mg weekly x4 then 1200 mg q2w maintenance for adults).weight- and indication-specific per document

    See chunks 60-61

    Botox (onabotulinumtoxinA): Per-indication maximum Units per treatment and minimum retreat intervals (adults: up to 400 Units per 12-week interval; pediatric weight-based caps where specified).per-indication unit limits and retreat intervals

    See chunk 63

    Ranibizumab biosimilars (Byooviz, Cimerli): Intravitreal 0.3–0.5 mg per affected eye every month (approx. 28 days) depending on product and indication; may dose less frequently after initial monthly dosing where noted.0.3 mg or 0.5 mg monthly per affected eye

    See chunks 72-73

    Coverage limited to listed quantity limits

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis and route of administration.

    General rule: Medication is covered when administered for the listed diagnosis at or below the specified route, dose, and frequency in this segment.per-entry dosing limits

    See individual medication entries in chunks 72-91 for exact values.

    Medication-specific maximum dosing (quantity limits)

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis

    General rule: Use the medication for the listed diagnosis and do not exceed the specified Maximum Dosing Regimen (route, dose, frequency).see per-diagnosis entries below

    This module is a compilation of per-diagnosis maximum dosing entries; each entry functions as an individual criterion limiting quantity.

    Diagnosis-specific maximum dosing regimens (by product)

    Covered dosing regimens (maximum) by diagnosis for specified IVIG products, effective 10/1/2025:

    HIV-Associated Thrombocytopenia: Intravenous 1 g/kg daily for 2 days; may repeat if needed.1 g/kg x 2 days

    chunk 108

    Idiopathic Thrombocytopenic Purpura (ITP): Intravenous 1 g/kg once daily for 2 days (may repeat) or alternatives such as 400 mg/kg daily x5 days as specified by product entries.1 g/kg x 2 days or alternatives

    chunks 108,127

    Kawasaki Syndrome: <18 years: 2 g/kg as a single dose; repeat if needed.2 g/kg single dose (pediatric)

    chunks 108,127

    Management of Immune Checkpoint Inhibitor-Related Toxicities: Intravenous 2 g/kg per treatment, divided over 2–5 consecutive days.2 g/kg

    chunk 109

    Product- and indication-specific maximum dosing (examples)

    Covered when dosing is within the listed maximum regimen for the specified product and diagnosis

    Gammagard S/D - Varicella Prophylaxis: Route: IV; Maximum Dosing Regimen: 400 mg/kg once as soon as possible and within 10 days after exposure.400 mg/kg once within 10 days

    chunk 126

    Gammaked - Typical acute indications: Typical maximum: 2 g/kg per treatment divided over 1–5 consecutive days; maintenance or repeat intervals specified per indication.2 g/kg divided over 1-5 days; repeat frequency per indication

    chunks 126-128

    Gammaked - Weekly HSCT/BMT regimens: Some indications list 800 mg/kg every week for transplant support where specified.800 mg/kg weekly where specified

    chunk 128

    Indication-specific maximum dosing (excerpt)

    Covered when dosing does not exceed the stated maximum regimen for the specified diagnosis (as provided below).

    Gammaplex – Pediatric HIV prophylaxis: Route: IV; <18 years: 400 mg/kg every 2 weeks.400 mg/kg every 2 weeks

    chunk 144

    Gammaplex – Rasmussen Encephalitis: Route: IV; 400 mg/kg daily for 5 days every 4 weeks.400 mg/kg daily x5 every 4 weeks

    chunk 144

    Gammaplex – Renal Transplantation (live donor): Route: IV; 400 mg/kg daily for 5 days every 4 weeks or 2 g/kg per dose for ABO incompatibility/positive crossmatch as listed.400 mg/kg x5 days q4wks or 2 g/kg per dose

    chunk 144

    Gamunex-C – CIDP: Initial: 2 g/kg divided over 2–5 days; Maintenance: 1 g/kg divided over 1–2 days every 3 weeks.Initial 2 g/kg; maintenance 1 g/kg q3wks

    chunk 148

    Gamunex-C – Kawasaki Syndrome: <18 years: 2 g/kg as a single dose; repeat if needed.2 g/kg single dose

    chunk 152

    Gamunex-C / Gammaplex – Stevens-Johnson Syndrome / TEN: IV 3 g/kg divided over 1–5 consecutive days (max 1 g/kg/day); repeat if needed as specified.3 g/kg divided over 1–5 days (max 1 g/kg/day)

    chunks 152,154

    Maximum dosing regimens (per drug and indication)

    Coverage is subject to the listed maximum dosing regimens per drug and indication (effective 10/1/2025).

    Trastuzumab products – example regimens: Multiple trastuzumab products list indication-specific initial and maintenance dosing (examples: IV initial 8 mg/kg once then 6 mg/kg every 3 weeks; alternative weekly 4 mg/kg then 2 mg/kg weekly; intrathecal 150 mg weekly for leptomeningeal disease).see product-specific entries

    chunks 162-164

    Hizentra / Hyqvia – immunoglobulin examples: SC/SC‑H products list weekly or q3w dosing equivalent to IVIG maxima (e.g., Hizentra 365 mg/kg weekly based on 800 mg/kg IV q3w; Hyqvia 1 g/kg every 3 weeks for CIDP).see text

    chunks 164-166

    Infliximab/Infliximab biosimilars: Multiple autoimmune/inflammatory indications with induction (weeks 0,2,6) and maintenance schedules (e.g., 5 mg/kg then maintenance q6–8 weeks) and permitted escalation to 10 mg/kg for certain diagnoses or incomplete response.see source

    chunks 171-174

    Bevacizumab (various brands): Oncology and ophthalmic indications with IV or intravitreal dosing (examples: IV 5–15 mg/kg every 2–3 weeks depending on indication; intravitreal 1.25–2.5 mg per affected eye every ~4 weeks; pediatric ROP 0.625 mg single dose).see text

    chunks 177-181

    Medication-specific maximum dosing regimens (select examples)

    Covered when dosing does not exceed the listed maximum dosing regimen for the specified diagnosis (entries shown are maximum dosing regimens effective 10/1/2025).

    Example - Bevacizumab (Jobevne) for Renal Cell Carcinoma: IV 10 mg/kg every 2 weeks (maximum regimen).Maximum dosing regimen

    chunk 177/180

    Example - Ranibizumab (Lucentis) for Diabetic Macular Edema: Intravitreal 0.3 mg per affected eye every month (~28 days) or 0.5 mg per affected eye monthly depending on product — use per-product entry.Maximum dosing regimen

    chunk 72

    Example - Pembrolizumab (Keytruda) dosing patterns: Typical oncology regimens include IV 200 mg every 3 weeks or 400 mg every 6 weeks for many indications; pediatric weight-based alternatives may apply.Maximum dosing regimen

    chunks 162/199

    Coverage conditioned on adherence to listed maximum dosing regimens

    Covered when ALL of the following are met:

    Conformance to dosing limits: The requested medication is for a listed indication and the requested dose, route, frequency, and total quantity do not exceed the maximum dosing regimen specified for that indication.as specified per entry

    Multiple entries list age- or weight-based limits (see respective medication entries).

    Age/weight restrictions: Member meets any age or weight criteria listed for the dosing regimen (e.g., adult intravitreal dosing ≥18 years; pediatric ROP dosing <18 years at 0.625 mg one dose; pegfilgrastim pediatric weight bands).as specified per entry

    See source for weight and age bands.

    Timing relative to chemotherapy for pegfilgrastim products: For prevention of febrile neutropenia, pegfilgrastim products should not be administered between 14 days prior to and 24 hours after chemotherapy.14 days prior to and 24 hours after

    See chunks 104,206 for Neulasta/Nyvepria/Fulphila guidance.

    Maximum dosing limits — covered when within limits

    Covered when dosing does not exceed the listed maximum regimen for the specified diagnosis and route of administration.

    Octagam: Major indications: Octagam IV maximum dosing examples: 800 mg/kg every 3 weeks for certain indications; solid-organ transplant allosensitized members 3 g/kg divided over 2–5 days (max 1 g/kg/day) every 2–4 weeks; Stevens‑Johnson/TEN 3 g/kg divided over 1–5 days; SLE 2 g/kg divided over 2–5 days every 4 weeks; varicella prophylaxis 400 mg/kg once within specified window.per-chunk dosing per diagnosis

    See chunks 216-217

    Trastuzumab biosimilars (Ogivri/Ontruzant): Multiple oncology indications with initial and maintenance dosing listed (e.g., IV 4 mg/kg once then 2 mg/kg weekly, or 8 mg/kg once then 6 mg/kg q3w; intrathecal 150 mg weekly for leptomeningeal disease).initial and maintenance regimen per diagnosis

    See chunks 219,224

    Omlyclo (omalizumab) dosing: Indication- and age/weight-based SC dosing bands (examples: chronic spontaneous urticaria age ≥12 yrs 300 mg every 4 weeks; asthma and other indications with 600 mg every 2 weeks where specified).age/weight-specific dosing bands

    See chunk 221

    Opdivo (nivolumab) dosing examples: Numerous cancer indications with IV dosing options such as initial 3 mg/kg every 3 weeks then maintenance fixed dosing (e.g., 240 mg q2w or 480 mg q4w) or weight-based pediatric alternatives per indication.indication-specific dosing schedules

    See chunks 224,229

    Opuviz (aflibercept) ophthalmic dosing: Intravitreal initial 2 mg per affected eye every 4 weeks for 5 doses; maintenance 2 mg every 4 weeks (approximately every 25 days).intravitreal per-eye dosing

    See chunks 234-235

    Medication-specific maximum dosing (quantity limits)

    Covered when dosing and diagnosis match the listed maximum dosing regimens for each medication:

    Opdivo Qvantig dosing by diagnosis: Subcutaneous dosing options by diagnosis include 600/10,000 mg‑units every 2 weeks, 900/15,000 mg‑units every 3 weeks, or 1200/20,000 mg‑units every 4 weeks; initial and maintenance options vary by indication (e.g., urothelial carcinoma initial 900/15,000 mg‑units q3w then maintenance options as listed).per-product regimens

    See chunks 234-235

    Opuviz (aflibercept-yszy) ophthalmic dosing: Intravitreal initial 2 mg per affected eye every 4 weeks for 5 doses; maintenance 2 mg per affected eye every 4 weeks.per-eye dosing schedule

    See chunk 235

    Panzyga (IVIG) dosing examples: Panzyga IVIG maximum regimens include 2 g/kg divided over 2–5 days for many autoimmune indications; 800 mg/kg every 3 weeks for primary immunodeficiency; 400 mg/kg pediatric prophylaxis q2w; transplant/ABO incompatibility dosing 2 g/kg per dose as listed.per-indication regimens

    See chunks 247,253

    This section defines the payer's coverage approach for specialty medications by stating that items are covered only when administered at or below the maximum dosing regimens listed for each diagnosis, route, and patient age/weight band. For Actemra (tocilizumab), the document lists indication-specific IV regimens (for example, Castleman disease: 8 mg/kg IV every 2 weeks; giant cell arteritis: 6 mg/kg IV up to 600 mg every 4 weeks; cytokine release syndrome with pediatric weight bands and maximum absolute dose caps). Coverage is therefore conditioned on requests matching the specified route, dose (including mg/kg where applicable), frequency, and any age/weight thresholds shown in the dosing table.

    The excerpt does not list standalone exclusion paragraphs; instead, coverage limitations are implemented through explicit maximum dosing regimens and quantity limits. Where no separate exclusion text appears, items not meeting the per-indication dosing, frequency, age, or weight criteria in the tables will not meet the coverage conditions described.

    Any administration that exceeds the stated mg/kg dosing, absolute dose caps, or the permitted dosing frequency for the indicated diagnosis is outside the listed quantity limits and therefore not supported. In other words, requests for doses or schedules that are higher than the per-diagnosis maximum regimens (for example, IV doses above the listed mg/kg limits or more frequent administrations than the interval specified) may be excluded or subject to denial on quantity-limit grounds.

    Coding and Quantity Limit Details

    Bevacizumab entries (product-level, no billing codes)mixed
    not providedBevacizumab (Alymsys/Avastin/Mvasi/Avzivi) dosing entries by diagnosis and route (intravitreal and IV) are listed; no CPT/HCPCS/NDC codes present in excerpt.
    IVIG (Asceniv) entries (product-level, no billing codes)mixed
    not providedAsceniv (Immune Globulin Intravenous) dosing entries across many indications (e.g., 2 g/kg divided over 2–5 days; 800 mg/kg every 3 weeks; 3 g/kg divided over 1–5 days); no billing codes present in excerpt.
    Infliximab biosimilar entries (product-level, no billing codes)mixed
    not providedAvsola (Infliximab-axxq) dosing entries by diagnosis and age groups (e.g., induction 5 mg/kg weeks 0,2,6; maintenance every 8 weeks; up to 10 mg/kg in some cases); no billing codes present in excerpt.
    Medications referenced (no billing codes provided in excerpt)mixed
    Bevacizumab (Avastin/Avzivi/Mvasi)Anti-VEGF monoclonal antibody formulations with IV and intravitreal dosing limits referenced in the excerpt (no billing codes included).
    Infliximab-axxq (Avsola)Infliximab biosimilar with induction and maintenance dosing entries referenced (no billing codes included).
    Ranibizumab biosimilars (Byooviz, Cimerli)Intravitreal ranibizumab biosimilars referenced with per-eye dosing regimens (no billing codes included).
    Various IVIG products (Gammaplex, Gamunex-C, Bivigam, Panzyga, Octagam)Multiple IVIG products and their per-indication dosing limits are referenced without billing codes in the excerpt.
    Drugs with quantity limits (named products)mixed
    BivigamImmune Globulin Intravenous (Human) — multiple indication-specific maximum dosing regimens (e.g., 2 g/kg; 400 mg/kg; 800 mg/kg).
    BKEMVEculizumab-aaeb — dosing regimens for aHUS, gMG, PNH (weight- and indication-specific induction/maintenance schedules).
    BomyntraDenosumab-bnht — dosing regimens for giant cell tumor of bone, hypercalcemia, prevention of skeletal-related events (e.g., 120 mg days 1,8,15 then q4w).
    BotoxOnabotulinumtoxinA — per-indication unit maximums and retreat intervals (adult 400 Units max per 12 weeks; pediatric weight-based caps).
    BriumviUblituximab-xiiy — listed among named products with quantity limits in the excerpt (product-level entry shown; no billing codes included).
    Byooviz / CimerliRanibizumab biosimilars — intravitreal dosing per affected eye (e.g., 0.3–0.5 mg monthly) listed with quantity limits.
    Covered medications listed (no billing codes in excerpt)mixed
    GammaplexImmune Globulin Intravenous (Human) — multiple indication-specific dosing and prophylaxis regimens referenced; no billing codes in excerpt.
    Gamunex-CImmune Globulin Intravenous (Human) — CIDP, measles prophylaxis, multiple myeloma and other indications referenced; no billing codes in excerpt.
    Hizentra / HyqviaSubcutaneous immunoglobulin products referenced with weekly/3-week schedules and prophylaxis dosing; no billing codes in excerpt.
    Medications with specified quantity limitsmixed
    Mvasi (Bevacizumab-awwb)Bevacizumab biosimilar with multiple IV and intravitreal indication-specific dosing (e.g., IV 15 mg/kg q3w; IV 10 mg/kg q2w; intravitreal 1.25 mg q4w; ROP 0.625 mg single dose).
    Myobloc (RimabotulinumtoxinB)Maximum Units per indication listed (e.g., cervical dystonia 10000 Units; chronic sialorrhea 3500 Units) with minimum retreat intervals.
    Neulasta (Pegfilgrastim)Pegfilgrastim dosing examples for prevention of febrile neutropenia and ARS (e.g., ≥18 yrs 6 mg once per chemo cycle; timing restrictions relative to chemotherapy).
    Nucala (Mepolizumab)Mepolizumab dosing listed for asthma and eosinophilic conditions (e.g., asthma ≥12 yrs 100 mg q4w; EGPA ≥18 yrs 300 mg q4w as three 100-mg injections).
    Nyvepria (Pegfilgrastim-apgf)Pegfilgrastim-apgf with same dosing structure as pegfilgrastim products for FN prevention and stem cell indications (weight/age bands).
    Ocrevus (Ocrelizumab)Multiple sclerosis dosing (IV initial 300 mg then 300 mg at 2 weeks; maintenance 600 mg q6 months) referenced among products with quantity limits.
    OctagamImmune Globulin Intravenous (Human) — indication-specific regimens (e.g., 1 g/kg per day; 400 mg/kg q3w) referenced as having quantity limits.
    Maximum single dose cap — up to a maximum of 800 mg (multiple indications)
    Maximum single IV dose cap (multiple indications)Up to a maximum of 800 mg per IV administration
    Common IV per‑kg expressionIV dosing frequently expressed as mg/kg with absolute cap (e.g., 8 mg/kg with max 800 mg)
    Pediatric CRS/SJIA capsPediatric weight-based IV doses (see pediatric cutoffs) still capped at 800 mg maximum per dose
    Actemra maintenance cap exampleRheumatoid arthritis: 8 mg/kg up to 800 mg every 4 weeks
    Maximum single dose cap (GCA) — up to maximum of 600 mg every 4 weeks
    Giant cell arteritis (GCA) IV cap6 mg/kg (up to a maximum of 600 mg) every 4 weeks
    Adult dosing noteApplies to members ≥18 years for GCA
    Contrast with other Actemra capsOther indications use up to 800 mg cap; GCA uses 600 mg max
    Intravitreal minimum interval — no more frequent than every 4 weeks
    Intravitreal minimum intervalIntravitreal injections: no more frequent than every 4 weeks per affected eye
    Examples (Bevacizumab intravitreal)Alymsys/Avastin intravitreal: 1.25 mg or 1.5 mg per eye every 4 weeks; 2.5 mg for PCV not more often than q4w
    Pediatric ROP exceptionRetinopathy of prematurity: single 0.625 mg dose for neonates (not repeated more frequently than listed)
    Pediatric weight-based dosing cutoffs — e.g., <30 kg vs ≥30 kg dosing specified for cytokine release syndrome and SJIA
    Pediatric weight cutoffs for cytokine release syndrome (CRS)≥2 years: <30 kg = 12 mg/kg (up to 800 mg); ≥30 kg = 8 mg/kg (up to 800 mg); no more than 4 total doses given at least 8 hours apart
    Pediatric cutoffs for SJIA/Polyarticular JIA≥2 years: <30 kg = 12 mg/kg every 2 weeks (SJIA) or 10 mg/kg every 4 weeks (polyarticular/oligoarticular JIA) with separate ≥30 kg bands
    General ruleMany pediatric indications use <30 kg vs ≥30 kg bands to determine mg/kg dosing and apply the common 800 mg absolute cap
    BKEMV initial/maintenance weight-based thresholds — examples of initial and maintenance dosing and pediatric weight bands
    BKEMV (eculizumab) initial and maintenance examplesAdults: Initial 900 mg weekly x4; Maintenance 1200 mg every 2 weeks starting week 5
    Pediatric weight bands (aHUS examples)<18 yrs weight bands: 40–<...kg use 900 mg initial x4 then 1200 mg q2w; 30–<40 kg: initial 600 mg weekly x2 then 900 mg q2w starting wk3; 20–<30 kg: initial 600 mg x2 then 600 mg q2w; 10–<20 kg: initial 600 mg x1 then 300 mg q2w; 5–<10 kg: initial 300 mg x1 then 300 mg q3w
    gMG/PNH examplesgMG: initial 900 mg weekly x4 then 1200 mg q2w starting wk5; PNH: initial 600 mg weekly x4 then 900 mg q2w starting wk5
    Botox 12-week cumulative maximum — ≥18 years: up to 400 Units per 12-week interval (varies by indication)
    Botox 12‑week cumulative maximum (adults)≥18 years: maximum cumulative 400 Units per 12‑week interval (varies by indication)
    Pediatric per‑treatment weight‑based caps<18 years: 10 Units/kg up to specified per‑treatment maxima and a 12‑week cumulative cap (examples: max 340 Units for some weight bands)
    Retreatment intervalMany indications: may re‑treat no sooner than every 12 weeks (some indications specify 6 months)
    Cutaquig/Cuvitru weekly equivalent — 347 mg/kg every week (based on max IVIG dose of 800 mg/kg every 3 weeks)
    Cutaquig/Cuvitru weekly equivalent347 mg/kg every week (based on max IVIG dose of 800 mg/kg every 3 weeks)
    Flexible intervalsProvided the total weekly dose is maintained, dosing interval may range from daily up to biweekly for SC products
    SC post‑exposure prophylaxisCuvitru: 400 mg/kg once as soon as possible and within 6 days after measles exposure (SC)
    Epysqli (Eculizumab-aagh) adult maintenance dose — 1200 mg every 2 weeks (starting on week 5)
    Epysqli (Eculizumab-aagh) adult maintenanceMaintenance dose: 1200 mg every 2 weeks starting on week 5 (after initial weekly doses)
    Initial inductionInitial: 900 mg weekly for 4 doses prior to maintenance schedule
    Applies to multiple indicationsSame initial/maintenance regimen documented for Epysqli in gMG and PNH entries where applicable
    Eylea intravitreal initial dosing — 2 mg per affected eye every 4 weeks for initial 3-5 doses depending on indication
    Eylea intravitreal initial dosingInitial: 2 mg per affected eye every 4 weeks for initial 3–5 doses depending on indication
    MaintenanceMaintenance: 2 mg per affected eye every 4 weeks (approximately every 25 days) after initial course
    Indication examplesUsed for DME, diabetic retinopathy, neovascular AMD; initial course length varies by indication (3–5 doses)
    Pegfilgrastim dosing by weight/age — examples of adult and pediatric dosing per chemotherapy cycle
    Pegfilgrastim adult dosing per chemo cycle≥18 years: 6 mg once per chemotherapy cycle (Neulasta/Nyvepria/Fylnetra); do not administer between 14 days prior to and 24 hours after chemotherapy
    Pediatric/weight‑based examples<18 yrs: weight bands e.g., ≥45 kg = 6 mg once per cycle; 31–<45 kg = 4 mg; 21–<31 kg = 2.5 mg; 10–<21 kg = 1.5 mg; <10 kg = 0.1 mg/kg once per cycle
    Hematopoietic ARS dosingFor hematopoietic subsyndrome of ARS: 6 mg weekly x2 (adult) or weight‑banded weekly dosing for pediatric patients
    IVIG dosing limits — common entries include initial 2g/kg divided over 2-5 days, maintenance 1g/kg every 3 weeks, and ranges up to 3g/kg
    Common IVIG initial high‑dose regimensTypical acute/high‑dose regimen: 2 g/kg divided over 1–5 consecutive days
    Maintenance IVIG regimensCommon maintenance: 1 g/kg every 3 weeks or alternative maintenance intervals (e.g., 1–2 g/kg every 2–6 weeks depending on indication)
    Range of IVIG dosingIVIG dosing ranges in policy include 400 mg/kg (prophylaxis) up to 3 g/kg divided over 1–5 days (max 1 g/kg/day) for select indications
    Product examplesProducts with these regimens include Gammagard, Gammaplex, Gamunex‑C, Gammaked, Gammagard S/D, Flebogamma, Panzyga, Bivigam, etc.
    Time window for post-exposure prophylaxis — Measles/Varicella prophylaxis timing windows (e.g., measles within 6 days, varicella within 10 days)
    Time window for measles post‑exposure prophylaxisMeasles (rubeola) prophylaxis: IVIG 400 mg/kg once as soon as possible and within 6 days after exposure
    Time window for varicella post‑exposure prophylaxisVaricella prophylaxis: IVIG 400 mg/kg once as soon as possible and within 10 days after exposure (product‑dependent)
    SC product window examplesSome SC products list similar timing (e.g., Cuvitru measles prophylaxis: 400 mg/kg once within 6 days)
    Pediatric Kawasaki syndrome dose — <18 year(s) 2g/kg as a single dose
    Pediatric Kawasaki syndrome IVIG dose<18 years: 2 g/kg as a single IV dose (may repeat if needed)
    Product consistencyMultiple IVIG products (e.g., Gammaplex, Panzyga) list pediatric Kawasaki dosing as 2 g/kg single dose
    Documentation requiredProviders should document pediatric age and weight to support 2 g/kg single‑dose dosing
    Varicella/Measles prophylaxis single dose — 400mg/kg once as soon as possible
    Varicella/Measles prophylaxis single‑dose IVIG400 mg/kg once as soon as possible (varicella within 10 days after exposure; measles within 6 days for some products)
    Route and timingAdministered intravenously (some SC products specify similar timing for measles) and must be given within the stated exposure window
    Product examplesGammagard, Gammaplex, Gammaked, Flebogamma and others include the 400 mg/kg prophylaxis entry
    Common high-dose regimen for acute indications — 2g/kg divided over 1-5 days
    Common high‑dose acute IVIG regimen2 g/kg divided over 1–5 consecutive days (commonly used for acute autoimmune/neurologic indications)
    Typical use casesUsed for exacerbations, preparation for surgery, acute neurologic autoimmune diseases (e.g., CIDP exacerbation, ITP), and immune checkpoint toxicity
    Repeat/maintenance guidanceRepeat intervals vary by indication (e.g., every 4–12 weeks for some conditions) and are specified per diagnosis
    Pediatric IVIG dosing for prophylaxis — <18 year(s) 400mg/kg every 2 weeks
    Pediatric IVIG prophylaxis dosing<18 years: 400 mg/kg every 2 weeks for prophylaxis of bacterial infections in pediatric HIV and similar indications
    Product examplesListed for Gamunex‑C and other IVIG products; some SC products reference weekly equivalents
    DocumentationProvider should document pediatric age and weight when requesting prophylactic IVIG dosing
    High-dose IVIG regimen — 3 g/kg divided over 1–5 days (max 1 g/kg/day)
    High‑dose IVIG regimen (upper extreme)3 g/kg divided over 1–5 days (maximum 1 g/kg per day) for certain severe indications such as SJS/TEN or allo‑sensitization
    Per‑day maximumWhen using 3 g/kg courses the practical per‑day cap is 1 g/kg/day to respect the total per‑day limit
    Indication examplesApplied in select severe dermatologic, transplant‑related, or allo‑sensitization indications as specified by product entries
    Intravitreal dose per affected eye — ranges from 0.3mg to 2.5mg per affected eye depending on product and indication
    Intravitreal dose per affected eye rangeIntravitreal single‑eye doses range from 0.3 mg to 2.5 mg depending on product and indication (examples: Lucentis 0.3–0.5 mg; Mvasi/Bevacizumab 1.25–2.5 mg)
    Product/indication specificityDose and interval vary by product and diagnosis (e.g., Lucentis monthly 0.3–0.5 mg; Eylea 2 mg per eye monthly initial series)
    Pediatric intravitreal exampleROP (neonates): bevacizumab 0.625 mg single dose
    Timing relative to chemotherapy — Do not administer pegfilgrastim products between 14 days prior to and 24 hours after chemotherapy
    Timing relative to chemotherapy for pegfilgrastimDo not administer pegfilgrastim products between 14 days prior to and 24 hours after chemotherapy
    Rationale/coverage implicationRequests that fall within this disallowed window do not conform to the stated dosing guidance and may be denied
    Applies to all pegfilgrastim products listedNeulasta, Fulphila, Fylnetra, Nyvepria and biosimilars share this timing restriction
    Weight-based dosing thresholds — examples of age/weight stratified dosing
    Age/weight‑based dosing thresholds (general)Multiple agents use age and weight bands (e.g., <30 kg vs ≥30 kg for tocilizumab pediatrics; weight bands for eculizumab and pegfilgrastim) to determine dosing
    Examples — tocilizumabPediatrics ≥2 yrs: <30 kg vs ≥30 kg determine mg/kg dose and frequency (CRS/SJIA entries)
    Examples — eculizumab and pegfilgrastimEculizumab: multiple pediatric weight bands with initial/maintenance doses; pegfilgrastim: weight bands map to fixed mg doses in children
    Age/weight-based dosing thresholds — multiple agents use age and weight bands to determine dose
    Age/weight-based dosing thresholds (multiple agents)Policy uses age (e.g., ≥18, ≥2 years, <18) and weight bands (e.g., <30 kg, 10–<20 kg, 31–<45 kg, <56 kg, 56–<86 kg, ≥86 kg) across agents to define dosing
    Clinical implicationProviders must document member age and weight when dosing is mg/kg or when weight bands determine fixed dosing
    ExamplesTocilizumab, eculizumab, pegfilgrastim, IVIG products, and denosumab entries include explicit age/weight bands

    Provider Actions — Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior authorization required — confirm Actemra dose/frequency

    Prior authorization is required for Actemra (tocilizumab) requests to confirm the requested dose and frequency conform to the diagnosis-specific maximum dosing regimens (examples: Castleman disease IV 8 mg/kg every 2 weeks; CRS pediatric <30 kg 12 mg/kg up to 800 mg, ≥30 kg 8 mg/kg up to 800 mg, no more than 4 total doses; RA IV ≥18 years 8 mg/kg up to 800 mg every 4 weeks; GCA IV ≥18 years 6 mg/kg up to 600 mg every 4 weeks).

    • PA requests must specify diagnosis and the exact IV dose and frequency being requested (mg/kg and absolute mg where applicable).
    • PA approval will be evaluated against the listed maximum regimen for the member’s diagnosis and age/weight band.
    Prior Authorization

    Submit PA using the specified maximum dosing regimen

    Use the payer’s specified maximum dosing regimens by diagnosis and route when preparing authorization requests and for quantity‑limit review; approvals are intended only when dosing does not exceed those maxima.

    • For IV indications, include mg/kg dosing and any stated maximum absolute mg (e.g., max 800 mg for many Actemra entries).
    • For pediatric weight/age bands, document the applicable band and the corresponding dose.
    Prior Authorization

    Ensure PA matches per‑diagnosis dose limits and route

    Prior authorization requests must not exceed the diagnosis‑specific maximum dosing regimens and should reflect the route of administration and induction/maintenance schedule where listed (PA should match per‑diagnosis dose limits).

    • If the indication has induction and maintenance schedules, the PA should indicate which phase is being requested and the exact schedule (weeks/days).
    • Requests for higher mg/kg or more frequent dosing than listed are outside the published maxima and require justification; may be denied.
    Prior Authorization

    Adhere to listed maximum dosing regimens for quantity‑limit review

    Providers must adhere to the listed maximum dosing regimens for specialty medications subject to quantity limits; authorization and quantity‑limit review will align approvals to those maxima.

    • Coverage is limited to the maximum route, dose, frequency, and age/weight band shown for each diagnosis.
    • Requests exceeding those maximum regimens may be denied as outside quantity limits.
    Prior Authorization

    PA approvals align with published quantity limits

    Prior authorization approvals will align with the payer’s published quantity limits; the presence of maximum dosing regimens implies PA is required for specialty medication quantity requests and approvals will be limited to those regimens.

    • Treat the published maximum dosing regimens (dose, route, frequency) as the upper limit for covered quantities.
    • PA requests should not request quantities exceeding the listed maxima for the indicated diagnosis.
    Prior Authorization

    Quantity limits listed (PA implied; procedures not detailed)

    The policy section presents maximum dosing regimens (quantity limits) by diagnosis effective 10/1/2025; prior authorization is implied but specific PA procedures or codes are not included in this excerpt.

    • Providers should use the listed maximum dosing regimens as the basis for PA requests even though explicit PA instructions/codes are not provided here.
    • Effective date for the limits is 10/1/2025; cite this date when relevant to authorization requests.
    Prior Authorization

    PA procedures not specified in this excerpt — use dosing limits when requesting PA

    This excerpt does not state detailed prior authorization procedures; it provides only product‑ and diagnosis‑specific maximum dosing regimens—providers must still submit PA consistent with the listed dosing but should consult payer PA resources for procedural details.

    • Use the dosing/regimen entries in this document to populate PA requests, and reference the payer’s PA portal/forms for submission steps and codes.
    Prior Authorization

    PA approvals governed by product‑ and diagnosis‑specific maxima

    Prior authorization requests must match the product‑ and diagnosis‑specific maximum dosing regimens effective 10/1/2025; requests that deviate from the listed dosing/frequency should include clinical justification.

    • Requests should indicate the exact product, diagnosis, dose (mg/kg and absolute mg), route, frequency, and duration being requested.
    • Deviations from listed maxima commonly require additional documentation and are subject to denial.
    Prior Authorization

    Dosing limits specified — PA procedure/codes not provided in excerpt

    The excerpt specifies dosing limits effective 10/1/2025 for multiple specialty medications but does not provide PA procedure or affected billing codes; providers must still ensure requested dosing is within the stated maxima.

    • When requesting quantities for products like Gammaplex or Gamunex‑C, include the diagnosis and the dosing regimen exactly as listed.
    • Consult payer PA guidance for submission workflow and codes.
    Prior Authorization

    Ensure PA reflects the listed regimen and route

    Prior authorization requests should reflect the specified maximum dosing regimen and route of administration (e.g., trastuzumab initial and maintenance IV dosing, bevacizumab IV or intravitreal regimens) to be approved.

    • Include which formulation/route is requested (IV, intravitreal, SC) and the corresponding regimen tied to the diagnosis.
    • Age/weight bands stated in the limits must be applied when calculating requested dose.
    Prior Authorization

    PA not explicitly stated — dosing limits effective 10/1/2025

    This excerpt lists maximum dosing regimens and effective dates but does not state PA program rules; providers should treat PA as implied for specialty medication quantities and verify procedural requirements separately.

    • Effective date for the dosing limits is shown as 10/1/2025 and should be referenced for requests covering that period.
    Prior Authorization

    Conform to listed maximum dosing regimens for coverage

    Coverage and prior authorization are governed by the specified maximum dosing regimens effective 10/1/2025; providers must request coverage consistent with the listed dose, route, frequency, and any age/weight criteria.

    • PA requests that conform to the listed maxima are consistent with coverage; those exceeding maxima risk denial.
    • Identify product, diagnosis, dose per administration, frequency, and total quantity in the PA.
    Prior Authorization

    PA required for specialty medication quantity requests (implied)

    Prior authorization is implied by the presence of payer‑specified maximum dosing regimens tied to diagnoses; providers must request coverage consistent with the listed dose and diagnosis for specialty medication quantity requests.

    • Provide the diagnosis and the exact regimen (including mg/kg and maximum absolute mg where required) with the PA.
    • For pediatric dosing, include the member’s age and weight to demonstrate applicable banding.
    Prior Authorization

    PA implied — do not exceed published dosing limits

    Prior authorization is implied for specialty medications subject to these maximum dosing regimens; dosing must not exceed the published limits per diagnosis to be eligible for coverage.

    • When PA is submitted, include documentation tying the requested dose/frequency to the listed maximum regimen.
    • Requests for doses beyond published maxima should include clinical rationale and supporting records.
    Prior Authorization

    Use listed dosing regimens for prior authorization review

    The per‑diagnosis maximum dosing regimens listed in this section are typically used by prior authorization reviewers to validate requests; include the exact regimen and effective date when submitting.

    • Authorization reviewers will compare requested dose, route, frequency, and total quantity to the listed maximum regimen for the diagnosis.
    • If the requested regimen matches the listed maximum, approval is consistent with the policy.
    Step Therapy

    Step therapy not listed in this excerpt

    No step therapy requirements are specified in these chunks; the document does not list required prior treatments or step edits for the medications shown.

    • Providers should assume no step therapy rules are present here but confirm with payer formularies or PA resources if step edits apply elsewhere.
    Documentation Required

    Document diagnosis plus member weight and age for weight‑based dosing

    Document the member’s diagnosis and the member’s weight and age when dosing is specified by mg/kg or by pediatric age/weight bands; weight/age documentation supports dosing up to the listed maximum regimens.

    • CRS and SJIA examples require age and weight bands (e.g., ≥2 years and <30 kg vs ≥30 kg dosing).
    • Include weight (kg) and date measured in the medical record submitted with PA.
    Documentation Required

    Include diagnosis and precise dosing details in PA/documentation

    Providers should document the diagnosis and the exact dosing regimen being administered or requested (drug name, route, dose including mg/kg where applicable, dosing frequency, and indication).

    • For IVIG and other weight‑based products, specify mg/kg dosing, number of treatment days, and planned maintenance interval if applicable.
    • Include supporting clinical rationale in the record when dosing approaches the listed maximum.
    Billing Rule

    Match dose and route on PA and claims to the listed regimen

    Ensure prescription and administration claims match the diagnosis‑specific maximum dosing regimen and the specified route (IV vs intravitreal vs SC); mismatches may lead to review or denial.

    • If intravitreal dosing is billed, the PA and claim must reflect per‑eye mg and the allowed minimum interval (e.g., no more frequent than every 4 weeks).
    • For IV products, include mg/kg calculations and cap the dose at any stated absolute maximum (e.g., Actemra max 800 mg).
    Documentation Required

    Document indication and link to dosing regimen

    Medical records should explicitly link the dosing regimen to the documented diagnosis and indication; for example, tie IVIG dosing schedules to the specific diagnosis and maintenance plan in the chart.

    • Include indication‑specific notes (e.g., CIDP maintenance vs acute course) and dates of prior doses where relevant.
    • Document any prior response or rationale for maintenance versus induction dosing.
    Documentation Required

    Document diagnosis and dosing schedule per policy

    Providers should document diagnosis and dosing schedule consistent with the listed maximum dosing regimen for the product and indication when requesting coverage or submitting claims.

    • Provide the regimen phase (induction or maintenance), planned frequency, and total quantity requested.
    • For pediatric regimens, include age and measured weight to support the selected dose band.
    Documentation Required

    Document indication and administered/requested dose

    This section lists maximum dosing regimens per diagnosis for covered specialty medications; providers must document the indication and administered/requested dose to align with the stated maximum dosing regimen.

    • When dosing is weight‑based, include the member’s current weight and the mg/kg calculation used.
    • If requesting doses at or near the maximum, include clinical justification and prior treatment history as available.
    Documentation Required

    Required documentation: product, diagnosis, route, and regimen

    Prescriptions/authorizations for IVIG and other specialty products should reference the specific product, diagnosis, route, and adhere to the listed maximum dosing regimen and frequency.

    • For IVIG courses, state per‑treatment total mg/kg, how it will be divided over treatment days, and the planned repeat interval (e.g., 2 g/kg divided over 2–5 days; maintenance 1 g/kg every 3 weeks).
    • Include product name (e.g., Gammaplex, Gammagard) in the request.
    Documentation Required

    Document weight for weight‑based dosing requests

    When dosing is weight‑based, provide the member’s weight and the mg/kg calculation to support dosing up to the listed maximum regimens (examples: Parvovirus B19 PRCA maintenance 400 mg/kg q4w for HIV with CD4 <100).

    • Include weight in kilograms and date measured in the clinical record and in the PA.
    • For pediatric bands, include age in years and any weight cutoffs used to select the dose band.
    Documentation Required

    Document regimen phase (induction vs maintenance) and related details

    Providers must document diagnosis and dosing regimen consistent with the listed maximum dosing regimens (include route, dose per administration, schedule, and whether request is for initial/induction or maintenance dosing).

    • Indicate if the request is for induction (loading) dosing or maintenance dosing and include dates/intervals.
    • Attach prior administration records when requesting maintenance quantities.
    Documentation Required

    Provide diagnosis and dosing matching the listed maximum regimen

    Supply diagnosis and dosing details that exactly match the listed maximum dosing regimens (route, dose, frequency, and age/weight guidance) when seeking authorization; these entries are effective 10/1/2025 and govern coverage limits.

    • For entries with maintenance recommendations, include the planned maintenance interval and prior response to therapy if applicable.
    • Requests that do not match the listed regimen should include specific clinical rationale and supporting records.
    Denial Risk

    Denial risk — exceeding Actemra maximum dose or frequency

    Requests exceeding the specified maximum dosing regimens (dose mg/kg or frequency) for Actemra for the listed diagnoses may be denied; the policy sets the upper limits by diagnosis (e.g., CRS dosing limits, RA, GCA, Castleman disease).

    • Exceeding mg/kg dosing, absolute mg caps (e.g., 800 mg), or allowed number of doses (e.g., CRS no more than 4 total doses) may result in denial.
    • If higher dosing is clinically justified, include detailed supporting documentation with the PA.
    Denial Risk

    Denial risk — exceeding stated maximum dosing regimens

    Requests that exceed the stated maximum dosing regimens or frequencies for a given diagnosis may be denied; the document’s dosing maxima serve as coverage upper limits.

    • Intravitreal and IV products have per‑diagnosis maximums; dosing more frequently than the minimum interval (e.g., intravitreal no more frequent than every 4 weeks) or higher mg/kg amounts risks denial.
    • Provide justification and prior therapy details when requesting above‑limit dosing.
    Denial Risk

    Denial risk — quantity‑limit exceedance if dosing exceeds maxima

    Requests exceeding the specified maximum dosing regimens for a diagnosis (for example higher mg/kg or more frequent dosing than listed) will be treated as quantity‑limit exceedances and may be denied.

    • Quantity‑limit denials apply when the dose, route, frequency, or total quantity exceeds the listed maximum for the diagnosis.
    • Providers should confirm the applicable per‑diagnosis maximum before submitting claims or PA.
    Denial Risk

    Denial risk — exceeding per‑treatment or cumulative quantity limits

    Requests exceeding the specified maximum dosing regimens or frequency for the listed diagnoses (e.g., IVIG courses above 2 g/kg per treatment or Botox cumulative 12‑week maxima) may be denied as exceeding quantity limits.

    • For IVIG, common maximums include 2 g/kg per treatment (divided) and maintenance schedules; exceeding these may be denied.
    • For products with per‑treatment unit maxima (e.g., Botox), exceeding the cumulative limit in the specified interval risks denial.
    Denial Risk

    Denial risk — quantity‑limit denial for doses/schedules above maxima

    Requests exceeding the listed maximum dosing regimen (dose, route, frequency) for the specified diagnosis may be subject to quantity‑limit denial; ensure requested quantities conform to the per‑diagnosis maxima.

    • Where age/weight bands apply, ensure the member’s data place them in the correct band before computing requested dose.
    • Intravitreal treatments must respect per‑eye dose and minimum interval requirements.
    Denial Risk

    Denial risk implied — quantity‑limit exceedance may trigger denial

    Dosing limits and effective dates are provided which imply that requests exceeding listed maximum dosing regimens may trigger quantity‑limit denial under the payer's utilization controls.

    • The presence of explicit maxima functions as the payer’s coverage ceiling; exceeding those ceilings without justification risks denial.
    • Confirm the effective date (10/1/2025) applies to the request period.
    Denial Risk

    Denial risk — exceeding IVIG product/diagnosis maximum dosing

    Requests exceeding the specified maximum dosing regimens for a given IVIG product and diagnosis may be denied; follow the product‑ and diagnosis‑specific maxima when requesting coverage.

    • IVIG maxima commonly include 2 g/kg per treatment or product‑specific alternatives (e.g., 400 mg/kg single‑dose prophylaxis); exceeding these may be denied.
    • Provide clear documentation if a higher‑than‑listed dose is clinically necessary.
    Denial Risk

    Denial risk — exceeding published quantity limits

    Requests exceeding the listed maximum dosing regimens (quantity limits) may be denied; the policy’s maximum dosing regimens are the basis for coverage determinations.

    • When submitting PA or claims, verify the regimen does not exceed the product/diagnosis caps detailed in the policy.
    • If requesting beyond limits, include comprehensive clinical justification and prior therapy documentation.

    Background

    Actemra (tocilizumab) is an interleukin-6 (IL‑6) receptor antagonist used to treat multiple inflammatory and immune-mediated conditions. Dosing in the policy is indication-specific and often weight‑based for IV administration, with explicit pediatric versus adult cutoffs and maximum absolute dose caps (for example, many IV entries use mg/kg dosing with caps such as up to 800 mg).

    Definitions and Dosing Terms